Oritavancin

(Orbactiv)

Oritavancin

Drug updated on 11/13/2023

Dosage FormInjection (intravenous: 400 mg)
Drug ClassLipoglycopeptide antibacterials
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.